Please upgrade your browser.
Kidney Cancer Association Applauds UK's Decision to Approve Drug for Hard-to-Treat Advanced Stage Kidney Cancer.
"The lesson for us here in the U.S. is to weigh clinical trial data and make scientifically-based decisions, not cost decisions disguised in the new vernacular as 'comparative effectiveness'"
The 67-year-old father-of-four finally won his battle to get the costly drug paid for in December.
Women who consumed such fish at least once every week had a markedly lower risk of developing kidney cancer.
"On the downside, clearly there is discussion about reimportation (of drugs from countries with lower prices) ..."
Change of Tack Shows Policy Shift and Saves Lives
More than 2,000 investigators will present their latest research on topics in urology, including prostate, bladder and kidney cancer; benign prostatic hyperplasia (BPH, or enlarged prostate); and other genitourinary diseases and conditions.
"Our study suggests that patients with metastatic renal cell carcinoma who received sequential therapy with sorafenib first, followed by sunitinib at the time of sorafenib failure, had overall longer disease control..."
The NHS drugs watchdog NICE has in principle approved a kidney cancer drug which can increase survival by a year. Sunitinib is one of the first drugs to be approved under new guidance urging a more liberal approach to treatments which only marginally extend life.
Merck & Co. is not ruling out purchasing a major drugmaker as it looks "across the whole spectrum" of options, CEO Richard Clark said.
|Powered by NeonCRM|